EPR OF NEW LOW-SYMMETRY SITES OF CE3+ IN SRF2 AND BAF2 by Baker, J, Chaplin, D

NMR-ON OF TA-182 AND TA-183 IN FE by Allsop, A, Chaplin, D, Murray, D, Stone, N

NMR-ON OF TA-182 AND TA-183 IN FE by Allsop, A, Chaplin, D, Murray, D, Stone, N

Highly informative typing of the human TNF locus using six adjacent polymorphic markers. by Udalova, I, Nedospasov, SA, Webb, G, Chaplin, D, Turetskaya, R

Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. by Korbelik, M, Parkins, C, Shibuya, H, Cecic, I, Stratford, MR, Chaplin, D

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. by Galbraith, S, Chaplin, D, Lee, F, Stratford, MR, Locke, R, Vojnovic, B, Tozer, G

[A polymorphic markers for the p75 tumor necrosis factor receptor gene: use for analyzing disease linkage]. by Turetskaia, R, Varfolomeev, E, Lopukhina, A, Udalova, I, Kuprash, D, Krasil'nikov, A, Chaplin, D, Nedospasov, SA

Mean multidimentional function by Turetskaya, R, Varfolomeev, E, Lopukhina, A, Udalova, I, Kuprash, D, Krasil'Nikov, A, Chaplin, D, Nedospasov, SA

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. by Tozer, G, Prise, V, Wilson, J, Cemazar, M, Shan, S, Dewhirst, M, Barber, P, Vojnovic, B, Chaplin, D

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. by Davis, P, Dougherty, G, Blakey, D, Galbraith, S, Tozer, G, Holder, A, Naylor, M, Nolan, J, Stratford, MR, Chaplin, D, Hill, S

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results by Zweifel, M, Jayson, G, Reed, N, Osborne, R, Hassan, B, Shreeves, G, Poupard, L, Walicke, P, Balkissoon, J, Chaplin, D, Rustin, G

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. by Zweifel, M, Jayson, G, Reed, N, Osborne, R, Hassan, B, Ledermann, J, Shreeves, G, Poupard, L, Lu, S, Balkissoon, J, Chaplin, D, Rustin, G

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. by Rustin, G, Shreeves, G, Nathan, P, Gaya, A, Ganesan, T, Wang, D, Boxall, J, Poupard, L, Chaplin, D, Stratford, MR, Balkissoon, J, Zweifel, M

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. by Patterson, D, Zweifel, M, Middleton, MR, Price, P, Folkes, L, Stratford, MR, Ross, P, Halford, S, Peters, J, Balkissoon, J, Chaplin, D, Padhani, A, Rustin, G

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. by Shaked, Y, Tang, T, Woloszynek, J, Daenen, L, Man, S, Xu, P, Cai, SR, Arbeit, J, Voest, E, Chaplin, D, Smythe, J, Harris, A, Nathan, P, Judson, I, Rustin, G, Bertolini, F, Link, D, Kerbel, R